Ketamine for Treatment-Resistant Depression is organized by The American Psychiatric Association (APA).

Start Date : Jan 01, 2018
End Date: Dec 31, 2020

Accrediation:
This Course has been Approved for a maximum of 0.5 AMA PRA Category 1 Credits.

Description:
This presentation reviews, in detail, the results of randomized trials of intravenous or intranasal ketamine for treatment-resistant unipolar and bipolar major depression, highlighting methodological limitations of the most important studies and limitations of study findings for long-term ketamine administration. The presenter is a clinician familiar with the use of intravenous ketamine in acute settings at a major academic medical center.

Objectives
• Describe the key findings from the most important studies of the effectiveness and safety of low-dose ketamine for the acute management of treatment-resistant unipolar or bipolar major depression.
• Define the principal short- and long-term safety and tolerability concerns regarding the use of low-dose ketamine for the management of treatment-resistant unipolar or bipolar major depression.
• Discuss the methods applied at Mayo Clinic and clinical programming steps that have been undertaken in order to develop a ketamine infusion therapy service.

This course is currently offered as a free member benefit through the Course of the Month program. Promotional pricing valid from January 1-31, 2018.